These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 38143642)

  • 1. "Normal but Catastrophic" Euglycemic Diabetic Ketoacidosis Precipitated by Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report.
    Sarno MJF; Hernandez DPF; Matulac MO
    Cureus; 2023 Nov; 15(11):e49236. PubMed ID: 38143642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
    Dull RB; Spangler ML; Knezevich EL; Lau BM
    J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature.
    Mistry S; Eschler DC
    AACE Clin Case Rep; 2021; 7(1):17-19. PubMed ID: 33851013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fall, Fracture, and Two Episodes of Euglycemic Diabetic Ketoacidosis.
    Wasey W; Hutchings S; Dufner A; Okon D; Saleh S
    Cureus; 2022 Jun; 14(6):e25788. PubMed ID: 35812537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Euglycemic Diabetic Ketoacidosis in the Setting of SGLT2 Inhibitor Use and Hypertriglyceridemia: A Case Report and Review of Literature.
    Gajjar K; Luthra P
    Cureus; 2019 Apr; 11(4):e4384. PubMed ID: 31218148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors.
    Vitale RJ; Valtis YK; McDonnell ME; Palermo NE; Fisher NDL
    AACE Clin Case Rep; 2021; 7(1):10-13. PubMed ID: 33521255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed euDKA Associated With Dapagliflozin After Pancreatitis.
    Wu G; Wu S; Tang J; Wu H
    Clin Ther; 2023 Jul; 45(7):e167-e170. PubMed ID: 37248092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
    Diaz-Ramos A; Eilbert W; Marquez D
    Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Significance of Precise Diabetes Diagnosis: A Case of Euglycemic Diabetic Ketoacidosis Induced by the Introduction of Empagliflozin with Simultaneous Reduction of Insulin Dosage.
    Bińczyk W; Dróżdż O; Siudek B; Głuszczyk AM; Plizga JI; Grajnert FJ
    Eur J Case Rep Intern Med; 2024; 11(6):004567. PubMed ID: 38846667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus.
    Chauhan S; Manov A; Dhillon GS; Shah P
    Cureus; 2023 Jan; 15(1):e33892. PubMed ID: 36819400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe euglycemic diabetic ketoacidosis secondary to sodium-glucose co-transporter 2 inhibitor: case report and literature review.
    El Ess MS; ElRishi MA
    Ann Med Surg (Lond); 2023 May; 85(5):2097-2101. PubMed ID: 37228937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment.
    He Z; Lam K; Zhao W; Yang S; Li Y; Mo J; Gao S; Liang D; Qiu K; Huang M; Wu J
    Acta Diabetol; 2023 Mar; 60(3):401-411. PubMed ID: 36576563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis.
    Dutta S; Kumar T; Singh S; Ambwani S; Charan J; Varthya SB
    J Family Med Prim Care; 2022 Mar; 11(3):927-940. PubMed ID: 35495849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis Masked by Urinary Tract Infection.
    Chauhan S; Diaz V; Ogbu IR; Sanchez JRP; Manov AE; Shah P
    Cureus; 2024 Aug; 16(8):e66408. PubMed ID: 39246944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis in COVID-19-infected patients: A systematic review of case reports.
    Khedr A; Hennawi HA; Khan MK; Eissa A; Mir M; Rauf I; Nitesh J; Surani S; Khan SA
    World J Clin Cases; 2023 Aug; 11(24):5700-5709. PubMed ID: 37727728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risk of Euglycemic Diabetic Ketoacidosis Due to Low-carbohydrate Diet While Taking Empagliflozin: a Case Report].
    Yamamoto M; Ide N; Kitajima S; Obayashi M; Asada K; Matsushima S; Ito M
    Yakugaku Zasshi; 2019; 139(11):1479-1483. PubMed ID: 31685745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetic Ketoacidosis as an Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Real World Insights.
    Baek HS; Jeong C; Yang Y; Lee J; Lee J; Lee SH; Cho JH; Sohn TS; Son HS; Yoon KH; Lee EY
    Diabetes Metab J; 2024 Nov; 48(6):1169-1175. PubMed ID: 38853537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Euglycemic diabetic ketoacidosis: A missed diagnosis.
    Nasa P; Chaudhary S; Shrivastava PK; Singh A
    World J Diabetes; 2021 May; 12(5):514-523. PubMed ID: 33995841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis.
    Patel K; Nair A
    Cureus; 2022 Sep; 14(9):e29652. PubMed ID: 36320965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-Induced Euglycemic Diabetic Ketoacidosis: When to Stop the Drip.
    Zughaib MT; Patel K; Leka M; Affas S
    Cureus; 2022 Jan; 14(1):e21768. PubMed ID: 35251838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.